Testing for positive control activity in a thorough QTc study

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 3, 2008, Pages 517-528

  Zhang, Joanne ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Bldg #22 ^*  (United States)

Author keywords

Assay sensitivity; QTc interval; Statistical testing; Thorough QTc study

Indexed keywords

MOXIFLOXACIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROL GROUP; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; ELECTROCARDIOGRAPHY MONITORING; HEART REPOLARIZATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SAMPLE SIZE; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL MODEL; VALIDATION PROCESS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE; LONG QT SYNDROME; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICS;

CONTROL GROUPS; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 45849141270     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400801995478     Document Type: Article

References (13)

1. Benjamini, Y., Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 57:289-300.
2. Berger, R., Hsu, J. (1996). Bioequivalence trials, intersection-union tests and equivalence confidence sets. Statistical Science 11:283-319.
3. Boos, D., Hofffman, D., Kringe, R., Zhang, J. (2007). New confidence bounds for QT studies. Statistics in Medicine 26:3801-387.
4. Eaton, M., Muirhead, R., Mancuso, J., Kolluri, S. (2006). A confidence interval for the maximal mean QT interval change caused by drug effect. Drug Information Journal 40:267-271.
5. Hosmane, B., Locke, C. (2005). A simulation study of powering thorough QT/QTc studies and a normal approximation for planning purposes. Drug Information Journal 39:447-455.
6. ICH. (2005). ICH E14 Guidance. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. International Conference on Harmonization, May 2005, in Geneva, Switzerland.
7. Julious, S. A. (2004). Sample sizes for clinical trials with normal data. Statistics in Medicine 23:1921-1986.
8. Luo, S., Michler, K., Johnston, P., Macfarlane, P. W. (2004). A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGs. Journal of Electrocardiology 37(Suppl.):81-90.
9. Malik, M., Färbom, P., Batchvarov, V., Hnatkova, K., Camm, A. J. (2002). Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 87:220-228.
10. Patterson, S., Jones, B. (2006). Bioequivalence and Statistics in Clinical Pharmacology. Chapman & Hall/CRC.
11. Stass, H., Dalhoff, A., Kubitza, D., Schuhly, U. (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrobial Agents in Chemotherapy 42:2060-2065.
12. Zhang, J., Machado, S. (2007). Current E14-derived approach to design and statistical analysis of TQT studies. Presentation at ACCP Symposium, Baltimore, Maryland, May 2007.
13. Zhang, L., Brian, S. (2007). Sex differences in QT interval variability and implication on sample size of thorough QT study. Drug Information Journal 41:619-627.